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Abstract 30 
Background and aim: Colistin is increasingly being used as a ‘last-line’ therapy to 31 
treat infections caused by multi-drug resistant Acinetobacter baumannii (A. baumannii) 32 
isolates, when essentially no other options are available in these days. The aim of this 33 
study was to detect genes associated with Colistin resistance in A. baumannii.  34 
Methods: 121 isolates of A. baumannii were collected from clinical and environmental 35 
samples during 2016 to 2018 in Baghdad. Isolates were diagnosed as A. baumannii by 36 
using morphological tests, Vitek-2 system, 16SrRNA PCR amplification and 37 
sequencing. Antibiotic susceptibility test was carried out using disc diffusion method. 38 
Phenotypic detection of colistin resistance was performed by CHROMagarTM COL- 39 
APSE medium and broth microdilution method for the determination of the minimal 40 
inhibitory concentration (MIC). Molecular detection of genes responsible for colistin 41 
resistance in A. baumannii was performed by PCR.  42 
Results: 92 (76%) out of 121 A. baumannii isolates were colistin resistant. 26 (21.5%) 43 
out of 121 isolates showed positive growth on CHROM agar Acinetobacter base for 44 
MDR. PCR detected mcr-1, mcr-2 and mcr-3 genes in 89 (73.5%), 78 (64.5%) and 82 45 
(67.8%) in the A. baumannii isolates respectively. 78 (64.5%) out of 121 isolates 46 
harbored the integron intI2 gene and 81 (66.9%) contained intI3 gene. Moreover, 60 47 
(49.6 %) out of 121 isolates were positive for the quorum sensing Iasl gene 48 
Conclusion: The presence of a large percentage of colistin resistant A. baumannii 49 
strains in Baghdad may be due to the presence of mobile genetic elements and it is 50 
urgent to avoid unnecessary clinical use of colistin. 51 
Keyword: Colistin, Resistance, Acinetobacter, CHROMagar TM COL-APSE, pEtN 52 
gene, CMS, mobilized colistin resistance. 53 
 54 
Introduction 55 
      Colistin is a polymyxin E, which possesses cyclic deca-peptide linked to a fatty acyl 56 
chain by α-amide linkage. The only difference in structure between polymyxin E and 57 
B is a single amino acid 1. There are two forms of colistin that are commercially 58 
available for use : colistin sulfate and sodium colistin methanesulfonate (CMS) 2. In the 59 
 
3 
1970s, CMS was replaced by aminoglycosides because of the significant side effects of 60 
these antibiotics such as nephrotoxicity and neurotoxicity 3. 61 
     Colistin is an antibiotic that is significantly used against Gram-negative bacteria 4-5. 62 
Due to increased and sometimes-inappropriate use, a rise in colistin resistance was 63 
reported 6. The bacterial cell membrane can be disrupted by ploymyxins, which 64 
interfere with phospholipids leading to damage to the osmotic barrier 7.  Polymyxins 65 
are ploypeptide molecule with positive charge that act as antimicrobial by disrupting 66 
the cell membrane and leading to death of the cell. This disruption occurs as a result of 67 
polymyxins binding with negatively charge in lipid A moiety of lipopolysaccharides 68 
(LPS) 8. Resistance to colistin might occur by alteration in binding site in lipid A or 69 
efflux pumps 9. 70 
           The modification of lipopolysaccharide (LPS) is most prevalent method of 71 
resistance, which involves an addition of phosphoethanolamine (PEtN) groups. This is 72 
thought to alter the physical properties of the outer membrane, which leads to 73 
polymyxin resistance 7. They are many well-known of PEtN transferases for example 74 
EptA from E. coli, H. pylori and Vibrio cholerae. Another example is PmrC from A. 75 
baumannii. These enzymes are chromosomally encoded and catalyze the transfer of 76 
PEtN from phosphatidylethanolamine (PE) onto the lipid A moiety of LPS8.   77 
     Plasmid-mediated colistin (COL) resistance due to the Mobilized colistin resistance 78 
mcr-1 pEtN gene has recently been identified in Asian countries. Bacteria carrying the 79 
mcr-1 gene have been isolated from many clinical and environmental sources since it 80 
was first described. Moreover, these isolates are often pan-drug resistant (PDR was 81 
known as non‐susceptibility to all agents in all antimicrobial categories) or extensively 82 
drug resistant (XDR was known as non‐susceptibility to at least one agent in all but two 83 
or fewer antimicrobial categories , bacterial isolates remain susceptible to only one or 84 
two categories), which significantly limits the therapeutic options for those organisms 85 
10. Many studies have identified seven mcr gene families in addition to mcr-1:  mcr-2 86 
11, mcr-3 12, mcr-4 13, mcr-5 14, mcr-6 15, mcr-7 16 and mcr-8 17. 87 
      Acinetobacter baumannii (A. baumannii) is a multidrug resistant (MDR) bacteria 88 
that can spread to civilian hospitals by cross infection of injured military patients 89 
repatriated from war zones 18-19. Two different mechanisms of colistin resistance have 90 
been characterized in A. baumannii 20-21. The first mechanism includes complete 91 
inactivation of the lipid A biosynthetic pathway and loss of outer membrane LPS. This 92 
pathway could be inactivated by deletions, point mutations or insertions in any of three 93 
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genes (lpxA, lpxC, and lpxD) 22.  Consequently, the interaction between LPS and colistin 94 
can be prevented leading to increase the MICs of colistin. Colistin resistance due to 95 
LPS inactivation has been identified in laboratory mutants and recent clinical isolates 96 
23. The second mechanism of colistin resistance is mediated by the PmrAB two- 97 
component system 24-25. It has been shown that mutations in pmrB increased cell 98 
sensitivity to colistin more than 100 fold 24.  99 
Integrons are genetic elements that allow efficient capture and expression of exogenous 100 
genes that may lead to dissemination of antibiotic resistance, particularly among Gram- 101 
negative bacteria13, 16. Integrons are reported to play a main role in the distribution   of 102 
colistin resistance 24-25. 103 
         Antibiotic resistant bacteria communicate through quorum sensing (QS). Quorum 104 
sensing system is widely spread in bacteria, which possesses an important role in 105 
controlling virulence factors. Therefore, it is considered as a “speaking” system in 106 
bacterium 26. QS is a way bacteria secret chemical signals called auto-inducers to 107 
communicates with each other and  is often followed by alteration in expression in 108 
genes  expression 3, 10, 16. The persistent modification of bacterial species or strains is a 109 
global issue. Both gram-positive and gram-negative bacteria uses inducer called 110 
acylated homoserine lactones (AHLs) as a chemical signal or auto chemo-inducer. 111 
Although the mechanisms of signaling are different from species to species 3, 10, 16, . QS- 112 
controlled gene expression plays a major role in the antibiotic resistant in pathogens. 113 
The aim of this study was to detect genes, which might be associated with colistin 114 
resistance in A. baumannii. As a result of the increasing distribution of serious 115 
infections with gram negative bacteria, colistin is increasingly being used as therapy to 116 
treat infections caused by MDR A. baumannii because there is a lack of other options. 117 
 118 
 119 
Material and Methods 120 
This work was done as a collaboration between Mustansiriyah University, Iraq, Assiut 121 
University, Egypt and University of Cincinnati medical center, USA. 122 
 In this study, 121 isolates of A. baumannii were collected from clinical (30 isolates 123 
from urine samples, 47 isolates from blood, 31 isolates from wound swabs, 4 isolates  124 
from cerebrospinal fluid and one isolate from endotracheal tube) and environmental  ( 125 
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8 isolates from soil)  samples from different hospitals across Baghdad during 2016 - 126 
2018. 127 
Detection of A. baumannii: 128 
The phenotypic characterization was performed using morphological tests, 129 
CHROMagar Acinetobacter, and Vitek-2 system (BioMérieux, France). 130 
Conventional PCR was performed for the genotypic identification of A. baumannii 131 
species using specific primers for 16SrRNA gene as previously described.27 132 
 The sequence of the primers and PCR cycling conditions are listed in Table (1). 133 
 134 
Phenotypic detection of colistin resistance in A. baumannii: 135 
We used CHROMagarTM COL-APSE (Paris, France) media for detection of colistin 136 
resistance and broth microdilution method for the determination of minimal inhibitory 137 
concentrations (MIC). Broth microdilution is recommended by CLSI for testing colistin 138 
susceptibility. Strains which showed colistin MIC values >2 μg/mL were interpreted as 139 
resistant according to CLSI, 2016 breakpoints (24), and using quality controlled standard 140 
strains (Acinetobacter baumanii ATCC BAA-747) obtained from American Type 141 
Culture Collection. 142 
 143 
Phenotypic detection of MDR in A. baumannii 144 
Then used CHROMagar Acinetobacter Base with supplement (S) and MDR 145 
Supplement for detection on MDR isolates (MDR: resistance to C3G, quinolones, 146 
carbapenem etc). We prepared CHROMagarTM COL-APSE plates using dehydrated 147 
CHROMagarTM base media (X207B) with the CHROMagarTM COL-APSE supplement 148 
(X207S) + CHROMagarTM Anti-swarming supplement (X208). These mediums were 149 
not autoclaved in order preserve the CHROMogenic compounds included in the 150 
mixture and instead were sterilized by boiling at 100°C while swirling or stirring 151 
regularly, prior to the addition of the supplements.  152 
 153 
The antibiotic susceptibility profile for A. baumannii isolates was determined 154 
using Kirby-Bauer disc diffusion test and interpreted as recommended by Clinical 155 
Laboratory Standards Institute (24). Susceptibility testing was performed by inoculating 156 
Mueller-Hinton agar plates (Thermo Fisher Scientific and Waltham, MA, USA) used 157 
the suspension equivalent in turbidity to 0.5 McFarland. Then, we incubated the plates 158 
overnight at 37°C before recording the results.  159 
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 160 
The following commonly used antibiotics were tested: ampicillin, amoxycillin, 161 
aztreonam, cefepime, cefotaxime, cefoperazone, ceftazidime, imipenem, meropenem, 162 
clindamycin, colistin, gentamicin, amikacin, tetracycline, chloramphenicol, 163 
ciprofloxacin, amoxycillin/clavulanic acid and trimethoprime/sulphamethoxazole.     164 
   165 
Molecular detection of Colistin resistance genes: 166 
      The entire genomic DNA extraction was performed for all resistance isolates 167 
according to modified Microwave lysis method 25.  168 
Colistin resistance genes mcr-1, mcr-2 and mcr-3 were detected by PCR for all isolates 169 
.APSE-COL TMgrown on CHROMagar 170 
The primer sequences and the amplicon size of different genes are listed in Table (1). 171 
Briefly, the PCR reaction mixture consisted of 12.5 μl of 2X GoTaq®Green Master 172 
Mix (KAPA, South Africa), 3 μl template DNA, 2 μl primers for each forward and 173 
reverse primers with final concentration (0.6 pmol/ μl), and complete the volume to 25 174 
μl with nuclease free water. The amplified PCR product was run in agarose gel 175 
electrophoresis and compared with 100 bp DNA ladder (KAPA, South Africa) and then 176 
visualized under UV trans-illuminator.  177 
 178 
Detection of integrons on colistin resistant A. baumannii: 179 
PCR was used to detect intI2 and intI3 genes, which represent the class 2 and class 3 180 
integrons that are known to be associated with MDR A. baumannii. The primer 181 
sequences and the amplicon size of genes are listed in Table (1). 182 
 183 
Detection of quorum sensing in colistin resistant A. baumannii: 184 
The presences of Iasl gene, as a part of the QS system, was investigated by PCR in A. 185 
baumannii isolates. The primer sequences and the amplicon size of different genes are 186 
listed in Table (1). 187 
 Results and Discussion  188 
-Phenotypic properties  189 
     121 isolates of A. baumannii were collected from different samples during 2016 to 190 
2018 in Baghdad. 16SrRNA PCR amplification and sequencing were used to identify 191 
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A. baumannii isolates. A. baumannii is gram negative, can cause many infections due 192 
to its multi-drug resistance (18, 20, 25).  193 
 26 (21.5%) out of 121 isolates showed positive growth with red colonies on  CHROM agar 194 
Acinetobacter base for MDR suggesting the isolates were resistant to C3G, quinolones and 195 
carbapenem (CHROMagarTM Acinetobacter, 2018). The source of these 26 MDR isolates 196 
was environmental sample (n=1), from urinary tract infections (n=2), blood (n=12), wound 197 
swabs (n=6), cerebrospinal fluid (n=4) and endotracheal tube (n=1)  198 
- Resistance of Acinetobacter: 199 
     The ability of the isolates to resist colistin was investigated by using CHROMagarTM 200 
COL-APSE (Paris, France) medium and confirmed by broth microdilution for 201 
determination of MIC. Isolates were detected by cream colonies on this medium 202 
(CHROMagar™ COL-APSE, 2018). The results showed that 92(76.03%) isolates 203 
(including one environmental isolate) showed positive growth on the CHROMagarTM 204 
COL-APSE medium. In addition, the MIC for these isolate was measured using broth 205 
microdilution for determination of MIC. The isolates showed MIC value ranged from 206 
4 to 16 g/ml. 207 
Antibiotic susceptibility pattern of A. baumannii isolated from clinical and 208 
environmental samples for different classes of antibiotics showed in Table (2). The 209 
result showed that the isolates were 100% resistant to β-lactum and Cefotaxime 210 
antibiotics, while they were less resistant (30%) to Tetracycline. PCR were performed 211 
to investigate the mcr related genes and their role in the resistance of A. baumannii 212 
    The mcr-1 gene was detected in 89 (73.6%) isolates; the mcr-2 gene detected in 78 213 
(64.5%) and the mcr-3 gene was detected in 82 (67.7%) in the A. baumannii (Table 3).   214 
     215 
CHROMagar COL-APSE medium was able to support the growth of colistin 216 
resistant Gram-negative bacteria because it is a sensitive and specific media for the 217 
growth of colistin resistant bacterial pathogens with a lower limit of detection of 101 218 
CFU 26. Resistance to antibiotic is a global issue. The limitation of effective treatment 219 
carbapenem treatment is leading to reduce treatment options for multidrug resistant 220 
bacteria 28-34. The (mobilized colistin resistance) mcr-1 gene has been reported in 221 
Escherichia coli and Klebsella pneumoniae from China, which encodes 222 
phosphoethanolamine transferase 10. It has the ability to be transferred between different 223 
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bacterial strains. This leads to antibiotic resistance because of alterations in the bacterial 224 
cell membrane lipid A 10, 23, 35. Gene mcr-2 has been reported in 76% of bacteria with 225 
mcr-1 gene from Belgium 11.  In addition, mcr-3 gene has been recently reported in E. 226 
coli of pig origin, which showed a 45.0% and 47.0% identity in nucleotide sequence to 227 
mcr-1 and mcr-2, respectively 12.   228 
     Results highlighted the rapid spreading of mcr-1, mcr-2 and mcr-3 genes globally. 229 
Recently, mcr-1 has been isolated from Enterobacteriaceae (animals), products of 230 
animals, humans and environments in more than thirty different countries from five 231 
continents 36. This rapid increase in the reporting of resistance mechanism in a short 232 
time is alarming. 233 
 234 
- Role of integrons on MDR distribution 235 
PCR was used to detect the class 2 and class 3 integrons in isolates of Acinetobacter 236 
baumannii, which associated with multi-drugs resistances. The results showed out of 237 
121 isolates, 78 (64.5%) harbored intI2 gene and 81 (66.9%) contained intI3 gene 238 
(Table 3). These results confirmed the role of integrons in MDS distribution in A. 239 
baumannii, which is similar to the role of integrons in the distribution of MDR in 240 
Salmonella spp. in Rajaei, et al. 37.  241 
         Integron genes play a key role in the horizontal transfer of antibiotic multi- 242 
resistance companying with genetic element. Resistance genes are either on the host 243 
plasmid or bacterial chromosome 13, 38-39. The intI gene encodes for an integrase, which 244 
belongs to the tyrosine-recombinase family 40.  The activity of integrase includes 245 
recombination of separate DNA molecules as gene cassettes. Integrons   are divided 246 
into two subsets: the mobile integrons that are responsible for spreading the anti-drug 247 
resistance genes and super integrons. According to sequencing, there are five classes of 248 
integrons 41-42.  249 
         Integrons have the ability to capture the antibiotic resistance cassettes genes that 250 
lead to distribution of MDR and decrease the infection treatment options 43. Resistance 251 
cassettes have been reported in both gram negative bacteria and gram positive bacteria 252 
44-46. 253 
- Quorum sensing detection in Acinetobacter 254 
         This system was first discovered in 1994 by Dr. Peter Greenberg in Vibrio 255 
fischeri. The QS system is a chemical mediated cell-to-cell communication that can 256 
regulate gene expression and the activity of the group in communities 47. There are 257 
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many activities depending on the QS system such as production, secretion, and 258 
detection of small signaling molecules named Autoinducers (AIs) 48.  259 
     The presences of Iasl gene in Acinetobacter isolates were investigated by PCR.  260 
The results indicated that 60 (49.6 %) out of 121 isolates were positive for Iasl gene 261 
(Table 3). Bacteria use QS to regulate genes expression, facilitate pathogenic invasion 262 
and spread virulence factors 49. The QS controls local bacteria population and cell 263 
density, which make the bacteria behave as a collaborative community such as 264 
multicellular organism50. Bacterial QS regulates bioluminescence, competence, 265 
antibiotic production and secretion of virulence factors 51. This affects the formation of 266 
biofilm 52-53,  drug sensitivity 54 and bacterial virulence 55. 267 
The lasI gene is as a part of QS system, the product of this gene being N-(3-oxo- 268 
dodecanoyl) -L- homoserine lactone (3-oxo-C12-AHL), which interacts with LasR and 269 
activates target promoters 56. Only  the multimeric form of this protein is active and can 270 
bind to target DNA and regulate the transcription of multiple genes at high cell densities 271 
57.     272 
Conclusion  273 
MDR A. baumannii is considered to be a serious threat. The current study showed that 274 
there is a high prevalence of colistin resistance in A. baumannii strains isolated from 275 
Iraq. This is associated with the ability of this pathogen to acquire new genetic material 276 
leading to increase the resistance. In addition, integrons showed a major role in 277 
extending the bacterial ability to grow in different challenge conditions because it 278 
allows A. baumannii to capture additional genetic material from other species. This 279 
leads to the distribution and increased the resistance of A. baumannii. This resistance 280 
can transform in over the world by natural transformation. The presence of a large 281 
percentage of colistin resistant A. baumannii strains in Baghdad makes it urgent to avoid 282 
unnecessary clinical use of colistin. 283 
 284 
 285 
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Table 1:  The PCR primers used and the amplicon size of different genes involved in this study 474 
27 475 
Gene Sequence TM (ºC)  
Products 
size (bp) 
16srRNA 
5'-TTTAAGCGAGGAGGAGG-3' 
5'-ATTCTACCATCCTCTCCC-3' 
58 240 
mcr-1 
5'-CACTTATGGCACGGTCTATGA-3' 
5'-CCCAAACCAATGATACGCAT-3' 
59 956 
mcr-2 
5'-:TGGTACAGCCCCTTTATT-3' 
5'-GCTTGAGATTGGGTTATGA-3' 
57 1,617 
mcr-3 
5-TTGGCACTGTATTTTGCATTT-3 
5-TTAACGAAATTGGCTGGAACA-3 
50 542 
intI2 
5'-CAC GGA TAT GCGACA AAA AGG-3' 
5'-TGTA GCA AAC GAGTGA CGA AAT G-3' 
60 788 
intI3 
5'-AGT GGG TGG CGAATG AGT G-3' 
5'-TGT TCT TGT ATCGGC AGG TG-3' 
60 600 
lasI 
5'- TCGACGAGATGGAAATCGATG-3' 
5'- GCTCGATGCCGATCTTCAG-3' 
59 402 
 476 
  477 
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Table (2): Antibiotic resistance pattern of A. baumannii isolates. 478 
 479 
 480 
 481 
 482 
  483 
Class of antibiotics Antibiotic tested A. of  121  rResistant strains fo
isolates baumannii  
 
penicillins Ampicillin 100 % 
Amoxycillin 100 % 
Monobactam Aztereonam 90% 
rd generation cephalosporin3  Cefotaxime 100 % 
Cefoperazone 85.9% 
Ceftazidine 93% 
4th generation cephalosporin    Cefepime 96% 
Carbapenemes Imipenem 44.7% 
Meropenem 36% 
Polypeptide Clindamycin 91.6% 
Colistin 76% 
Aminoglycosides Gentamicin 79% 
Amikacin 72% 
Tetracyclines Tetracycline 30% 
Amphenicols Chloramphenicol 72% 
quinolones Ciprofloxacin 79% 
Combination Amoxycillin/clavulanicacid 96% 
Trimethoprime/sulphametoxazole 91.6% 
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Table (3): Frequency of genes involved in colistin resistance in Acinetobacter baumannii isolates. 484 
PCR test  Positive result (%) Negative result 
mcr-1 89 (73.6%) 32 (26.4%) 
mcr-2 78 (64.5%) 43 (35.5%) 
mcr-3 82 (67.7%) 39 (32.2%) 
mcr-1+ mcr-2 74(61.1%) 47(38.8%) 
mcr-1+ mcr-3 77(63.6%) 44(36.3%) 
mcr-2+ mcr-3 69(57.02%) 52(42.9%) 
mcr-1+ mcr-2 + mcr-3 66(54.5%) 55(45.4%) 
intI2 78 (64.5%) 43 (35.5%) 
intI3 81 (66.9%) 40 (33.1%) 
lasI 60 (49.6%) 61 (50.4%) 
 485 
 486 
 487 
 488 
 489 
 490 
 491 
 492 
 493 
 494 
 495 
 496 
 497 
 498 
 499 
 500 
 501 
 502 
 503 
